Cost effectiveness analysis of elementary school-located vaccination against influenza-Results from a randomized controlled trial

Byung Kwang Yoo, Sharon G. Humiston, Peter G. Szilagyi, Stanley J. Schaffer, Christine Long, Maureen Kolasa

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

School-located vaccination against influenza (SLV-I) has been suggested to help meet the need for annual vaccination of large numbers of school-aged children with seasonal influenza vaccine. However, little is known about the cost and cost-effectiveness of SLV-I. We conducted a cost-analysis and a cost-effectiveness analysis based on a randomized controlled trial (RCT) of an SLV-I program implemented in Monroe County, New York during the 2009-2010 vaccination season. We hypothesized that SLV-I is more cost effective, or less-costly, compared to a conventional, office-located influenza vaccination delivery. First and second SLV-I clinics were offered in 21 intervention elementary schools (n= 9027 children) with standard of care (no SLV-I) in 11 control schools (n= 4534 children). The direct costs, to purchase and administer vaccines, were estimated from our RCT. The effectiveness measure, receipt of ≥1 dose of influenza vaccine, was 13.2 percentage points higher in SLV-I schools than control schools. The school costs ($9.16/dose in 2009 dollars) plus project costs ($23.00/dose) plus vendor costs excluding vaccine purchase ($19.89/dose) was higher in direct costs ($52.05/dose) than the previously reported mean/median cost [$38.23/$21.44 per dose] for providing influenza vaccination in pediatric practices. However SLV-I averted parent costs to visit medical practices ($35.08 per vaccine). Combining direct and averted costs through Monte Carlo Simulation, SLV-I costs were $19.26/dose in net costs, which is below practice-based influenza vaccination costs. The incremental cost-effectiveness ratio (ICER) was estimated to be $92.50 or $38.59 (also including averted parent costs). When additionally accounting for the costs averted by disease prevention (i.e., both reduced disease transmission to household members and reduced loss of productivity from caring for a sick child), the SLV-I model appears to be cost-saving to society, compared to "no vaccination" Our findings support the expanded implementation of SLV-I, but also the need to focus on efficient delivery to reduce direct costs.

Original languageEnglish (US)
Pages (from-to)2156-2164
Number of pages9
JournalVaccine
Volume31
Issue number17
DOIs
StatePublished - Apr 19 2013

Fingerprint

elementary schools
cost effectiveness
influenza
Human Influenza
Cost-Benefit Analysis
Vaccination
Randomized Controlled Trials
vaccination
Costs and Cost Analysis
dosage
vaccines
Vaccines
Influenza Vaccines
cost analysis
high schools
school children
Cost of Illness
disease prevention
disease transmission
Standard of Care

Keywords

  • Cost analysis
  • Cost effectiveness analysis
  • Randomized controlled trial
  • School-located vaccination against influenza

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Cost effectiveness analysis of elementary school-located vaccination against influenza-Results from a randomized controlled trial. / Yoo, Byung Kwang; Humiston, Sharon G.; Szilagyi, Peter G.; Schaffer, Stanley J.; Long, Christine; Kolasa, Maureen.

In: Vaccine, Vol. 31, No. 17, 19.04.2013, p. 2156-2164.

Research output: Contribution to journalArticle

Yoo, Byung Kwang ; Humiston, Sharon G. ; Szilagyi, Peter G. ; Schaffer, Stanley J. ; Long, Christine ; Kolasa, Maureen. / Cost effectiveness analysis of elementary school-located vaccination against influenza-Results from a randomized controlled trial. In: Vaccine. 2013 ; Vol. 31, No. 17. pp. 2156-2164.
@article{9fcc8fd4017b4dee8433d909a735da1a,
title = "Cost effectiveness analysis of elementary school-located vaccination against influenza-Results from a randomized controlled trial",
abstract = "School-located vaccination against influenza (SLV-I) has been suggested to help meet the need for annual vaccination of large numbers of school-aged children with seasonal influenza vaccine. However, little is known about the cost and cost-effectiveness of SLV-I. We conducted a cost-analysis and a cost-effectiveness analysis based on a randomized controlled trial (RCT) of an SLV-I program implemented in Monroe County, New York during the 2009-2010 vaccination season. We hypothesized that SLV-I is more cost effective, or less-costly, compared to a conventional, office-located influenza vaccination delivery. First and second SLV-I clinics were offered in 21 intervention elementary schools (n= 9027 children) with standard of care (no SLV-I) in 11 control schools (n= 4534 children). The direct costs, to purchase and administer vaccines, were estimated from our RCT. The effectiveness measure, receipt of ≥1 dose of influenza vaccine, was 13.2 percentage points higher in SLV-I schools than control schools. The school costs ($9.16/dose in 2009 dollars) plus project costs ($23.00/dose) plus vendor costs excluding vaccine purchase ($19.89/dose) was higher in direct costs ($52.05/dose) than the previously reported mean/median cost [$38.23/$21.44 per dose] for providing influenza vaccination in pediatric practices. However SLV-I averted parent costs to visit medical practices ($35.08 per vaccine). Combining direct and averted costs through Monte Carlo Simulation, SLV-I costs were $19.26/dose in net costs, which is below practice-based influenza vaccination costs. The incremental cost-effectiveness ratio (ICER) was estimated to be $92.50 or $38.59 (also including averted parent costs). When additionally accounting for the costs averted by disease prevention (i.e., both reduced disease transmission to household members and reduced loss of productivity from caring for a sick child), the SLV-I model appears to be cost-saving to society, compared to {"}no vaccination{"} Our findings support the expanded implementation of SLV-I, but also the need to focus on efficient delivery to reduce direct costs.",
keywords = "Cost analysis, Cost effectiveness analysis, Randomized controlled trial, School-located vaccination against influenza",
author = "Yoo, {Byung Kwang} and Humiston, {Sharon G.} and Szilagyi, {Peter G.} and Schaffer, {Stanley J.} and Christine Long and Maureen Kolasa",
year = "2013",
month = "4",
day = "19",
doi = "10.1016/j.vaccine.2013.02.052",
language = "English (US)",
volume = "31",
pages = "2156--2164",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "17",

}

TY - JOUR

T1 - Cost effectiveness analysis of elementary school-located vaccination against influenza-Results from a randomized controlled trial

AU - Yoo, Byung Kwang

AU - Humiston, Sharon G.

AU - Szilagyi, Peter G.

AU - Schaffer, Stanley J.

AU - Long, Christine

AU - Kolasa, Maureen

PY - 2013/4/19

Y1 - 2013/4/19

N2 - School-located vaccination against influenza (SLV-I) has been suggested to help meet the need for annual vaccination of large numbers of school-aged children with seasonal influenza vaccine. However, little is known about the cost and cost-effectiveness of SLV-I. We conducted a cost-analysis and a cost-effectiveness analysis based on a randomized controlled trial (RCT) of an SLV-I program implemented in Monroe County, New York during the 2009-2010 vaccination season. We hypothesized that SLV-I is more cost effective, or less-costly, compared to a conventional, office-located influenza vaccination delivery. First and second SLV-I clinics were offered in 21 intervention elementary schools (n= 9027 children) with standard of care (no SLV-I) in 11 control schools (n= 4534 children). The direct costs, to purchase and administer vaccines, were estimated from our RCT. The effectiveness measure, receipt of ≥1 dose of influenza vaccine, was 13.2 percentage points higher in SLV-I schools than control schools. The school costs ($9.16/dose in 2009 dollars) plus project costs ($23.00/dose) plus vendor costs excluding vaccine purchase ($19.89/dose) was higher in direct costs ($52.05/dose) than the previously reported mean/median cost [$38.23/$21.44 per dose] for providing influenza vaccination in pediatric practices. However SLV-I averted parent costs to visit medical practices ($35.08 per vaccine). Combining direct and averted costs through Monte Carlo Simulation, SLV-I costs were $19.26/dose in net costs, which is below practice-based influenza vaccination costs. The incremental cost-effectiveness ratio (ICER) was estimated to be $92.50 or $38.59 (also including averted parent costs). When additionally accounting for the costs averted by disease prevention (i.e., both reduced disease transmission to household members and reduced loss of productivity from caring for a sick child), the SLV-I model appears to be cost-saving to society, compared to "no vaccination" Our findings support the expanded implementation of SLV-I, but also the need to focus on efficient delivery to reduce direct costs.

AB - School-located vaccination against influenza (SLV-I) has been suggested to help meet the need for annual vaccination of large numbers of school-aged children with seasonal influenza vaccine. However, little is known about the cost and cost-effectiveness of SLV-I. We conducted a cost-analysis and a cost-effectiveness analysis based on a randomized controlled trial (RCT) of an SLV-I program implemented in Monroe County, New York during the 2009-2010 vaccination season. We hypothesized that SLV-I is more cost effective, or less-costly, compared to a conventional, office-located influenza vaccination delivery. First and second SLV-I clinics were offered in 21 intervention elementary schools (n= 9027 children) with standard of care (no SLV-I) in 11 control schools (n= 4534 children). The direct costs, to purchase and administer vaccines, were estimated from our RCT. The effectiveness measure, receipt of ≥1 dose of influenza vaccine, was 13.2 percentage points higher in SLV-I schools than control schools. The school costs ($9.16/dose in 2009 dollars) plus project costs ($23.00/dose) plus vendor costs excluding vaccine purchase ($19.89/dose) was higher in direct costs ($52.05/dose) than the previously reported mean/median cost [$38.23/$21.44 per dose] for providing influenza vaccination in pediatric practices. However SLV-I averted parent costs to visit medical practices ($35.08 per vaccine). Combining direct and averted costs through Monte Carlo Simulation, SLV-I costs were $19.26/dose in net costs, which is below practice-based influenza vaccination costs. The incremental cost-effectiveness ratio (ICER) was estimated to be $92.50 or $38.59 (also including averted parent costs). When additionally accounting for the costs averted by disease prevention (i.e., both reduced disease transmission to household members and reduced loss of productivity from caring for a sick child), the SLV-I model appears to be cost-saving to society, compared to "no vaccination" Our findings support the expanded implementation of SLV-I, but also the need to focus on efficient delivery to reduce direct costs.

KW - Cost analysis

KW - Cost effectiveness analysis

KW - Randomized controlled trial

KW - School-located vaccination against influenza

UR - http://www.scopus.com/inward/record.url?scp=84875858290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875858290&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2013.02.052

DO - 10.1016/j.vaccine.2013.02.052

M3 - Article

C2 - 23499607

AN - SCOPUS:84875858290

VL - 31

SP - 2156

EP - 2164

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 17

ER -